X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (25) 25
humans (21) 21
aged (18) 18
chemotherapy (16) 16
female (16) 16
male (16) 16
middle aged (15) 15
index medicus (12) 12
adult (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
lung neoplasms - drug therapy (8) 8
therapy (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer (7) 7
carcinoma (6) 6
survival (6) 6
aged, 80 and over (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
colorectal cancer (5) 5
combination (5) 5
drug therapy (5) 5
treatment outcome (5) 5
bevacizumab (4) 4
care and treatment (4) 4
clinical-trials (4) 4
efficacy (4) 4
elderly-patients (4) 4
epirubicin - administration & dosage (4) 4
epirubicin - adverse effects (4) 4
health aspects (4) 4
leucovorin (4) 4
lung neoplasms - mortality (4) 4
metastasis (4) 4
neutropenia (4) 4
neutropenia - chemically induced (4) 4
oxaliplatin (4) 4
survival analysis (4) 4
survival rate (4) 4
toxicity (4) 4
association (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
carcinoma, small cell - drug therapy (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
dose-response relationship, drug (3) 3
etoposide - administration & dosage (3) 3
fluorouracil (3) 3
fluorouracil - administration & dosage (3) 3
follow-up studies (3) 3
granulocyte colony-stimulating factor - administration & dosage (3) 3
immunotherapy (3) 3
lung neoplasms - pathology (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
quality of life (3) 3
randomized controlled trials as topic (3) 3
research (3) 3
safety (3) 3
supportive care (3) 3
trial (3) 3
vinblastine - administration & dosage (3) 3
vinblastine - analogs & derivatives (3) 3
1st-line treatment (2) 2
5-fluorouracil (2) 2
activation (2) 2
adenocarcinoma (2) 2
adverse events (2) 2
analysis (2) 2
antineoplastic agents - administration & dosage (2) 2
biopsy (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
breast-cancer (2) 2
camptothecin - analogs & derivatives (2) 2
cancer patients (2) 2
carboplatin - adverse effects (2) 2
cell biology (2) 2
cisplatin (2) 2
cisplatin - administration & dosage (2) 2
clinical-trials group (2) 2
colon cancer (2) 2
combined modality therapy (2) 2
criteria (2) 2
data cleaning (2) 2
declarative (2) 2
deterministic (2) 2
diagnosis (2) 2
diarrhea (2) 2
drug therapy, combination (2) 2
endocrine therapy (2) 2
ercc1 protein (2) 2
etoposide (2) 2
etoposide - adverse effects (2) 2
fluorouracil - therapeutic use (2) 2
glutathione transferase (2) 2
government interoperability frameworks (2) 2
granulocyte colony-stimulating factor - adverse effects (2) 2
granulocyte colony-stimulating factor - therapeutic use (2) 2
gstm1 protein (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Electronic Governance, ISSN 1742-7509, 2016, Volume 8, Issue 1, pp. 6 - 21
We consider the problem of handling digital identities within service-oriented architecture (SOA) architectures. We explore federated, single sign-on (SSO)... 
Single sign-on | Government interoperability frameworks | Web services | SOA | Federated identity | Service-oriented architecture | SSO | Governments | Platforms | Modules | Legacy | Electronics | Architecture (computers) | Interoperability | Standards
Journal Article
Journal Article
Lancet Oncology, ISSN 1470-2045, 2005, Volume 6, Issue 9, pp. 669 - 677
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 06/2019, Volume 234, Issue 6, pp. 7708 - 7717
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2014, Volume 4, Issue 1, pp. 6828 - 6828
Journal Article
Proceedings of the ACM SIGMOD International Conference on Management of Data, ISSN 0730-8078, 06/2016, Volume 26-, pp. 893 - 907
Conference Proceeding
Future Oncology, ISSN 1479-6694, 05/2012, Volume 8, Issue 5, pp. 625 - 630
Aims: A biosimilar medicine is one with proven similarity to a reference biological product for which the patent has expired and whose active ingredient is... 
filgrastim | febrile neutropenia | granulocyte colony-stimulating factor | biosimilars | ONCOLOGY
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2019, Volume 7, Issue 1, pp. 57 - 11
BackgroundRecent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer... 
Anti-PD-1/PD-L1 | Obesity | Immunotherapy | BMI | Cancer | Overweight | Anti-PD-1 | IMMUNOLOGY | CHEMOTHERAPY | FEATURES | MELANOMA | ONCOLOGY | INFLAMMATION | PD-L1 | NIVOLUMAB | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS | ADIPOSE-TISSUE | Body mass index | Treatment outcome | Cancer patients | Care and treatment | Usage | Analysis | Health aspects | Studies | Lung cancer | Melanoma | Response rates | Systematic review | Patients | Clinical outcomes | Tumors
Journal Article
Therapeutic Advances in Medical Oncology, ISSN 1758-8340, 1/2017, Volume 9, Issue 1, pp. 22 - 32
Background: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life... 
epoetin alfa | erythropoiesis-stimulating agents | biosimilar | chemotherapy-induced anaemia | erythropoietin | HEMOGLOBIN | CHEMOTHERAPY-INDUCED ANEMIA | SAFETY | GUIDELINES | PATTERNS | CANCER-TREATMENT ACT | EUROPE | ONCOLOGY | OUTCOMES | Original Research
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e327 - e337
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials... 
Autoimmune disease | Immune checkpoint inhibitors | Immunotherapy | Performance status | Anti‐programmed death‐1 | Sex | Anti-programmed death-1 | CRITERIA | MANAGEMENT | EFFICACY | IMMUNE-CHECKPOINT INHIBITORS | THERAPY | ONCOLOGY | ADVANCED MELANOMA | SEX-DIFFERENCES | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS
Journal Article
Journal of Universal Computer Science, ISSN 0948-695X, 2014, Volume 20, Issue 11, pp. 1543 - 1563
We discuss deployment solutions for e-Government Interoperability Frameworks (GIFs). We concentrate on middleware-oriented GIFs, i.e., those in which... 
E-Government | Government Interoperability Frameworks (GIF) | Service Level Agreements (SLA) | Middleware | Interoperability | Domain gateways | COMPUTER SCIENCE, SOFTWARE ENGINEERING | e-Government | interoperability | domain gateways | COMPUTER SCIENCE, THEORY & METHODS | middleware
Journal Article
International journal of cancer, ISSN 0020-7136, 07/2019
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers.... 
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 02/2019, Volume 20, Issue 2, pp. 192 - 200
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment... 
trastuzumab | metastatic breast cancer | pertuzumab | first-line treatment | HER2 | maintenance | endocrine therapy | SURVIVAL | EFFICACY | SAFETY | DOCETAXEL | CHEMOTHERAPY | PACLITAXEL | PHASE-II TRIAL | THERAPY | ONCOLOGY | CLEOPATRA | PLUS
Journal Article